Quick answer: Testosterone declines 1–2% per year after age 30, and by age 70 roughly 30% of men meet clinical criteria for hypogonadism — yet the majority go undiagnosed because standard total testosterone misses bioavailable hormone. Functional men’s health uses free testosterone, SHBG, DHEA-S, and the full metabolic-hormonal picture to restore vitality, protect the prostate, and address the root causes of testosterone decline before replacement therapy becomes necessary.
Men’s hormonal health rarely receives the nuanced attention it deserves. Conventional medicine typically measures total testosterone once, applies a binary pass/fail against a broad reference range, and either prescribes testosterone replacement therapy (TRT) or says “you’re fine.” Functional medicine asks a deeper question: why is testosterone declining, what metabolic and nutritional factors are driving it, and can we restore function without lifelong pharmaceutical dependency?
This article examines the clinical evidence behind testosterone optimization, prostate health, erectile dysfunction as a cardiovascular biomarker, BPH management, DHEA-S as a longevity marker, and the nutritional interventions that have demonstrated measurable benefit in peer-reviewed trials.
The Testosterone Decline Epidemic: What the Research Shows
The Baltimore Longitudinal Study on Aging, one of the most comprehensive longitudinal investigations of male aging, tracked testosterone levels in men across decades. Harman and colleagues (2001, Journal of Clinical Endocrinology & Metabolism) documented that total testosterone declines approximately 1.6% per year from peak levels, with free testosterone declining even faster — roughly 2–3% annually — due to age-related increases in sex hormone-binding globulin (SHBG). By age 70, nearly one in three men falls below the clinical threshold for hypogonadism.
What has attracted significant research attention, however, is a secular trend identified by Travison and colleagues (2007, Journal of Clinical Endocrinology & Metabolism): beyond age-related decline, population-wide testosterone levels have dropped substantially over the past several decades — independent of aging. A man at age 60 today has measurably lower testosterone than a man of the same age in 1985. The proposed drivers include increasing rates of obesity, insulin resistance, endocrine-disrupting chemical (EDC) exposure, chronic sleep deprivation, sedentary behavior, and chronic psychological stress — all of which suppress the hypothalamic-pituitary-gonadal (HPG) axis.
This distinction matters clinically. When testosterone is low due to reversible functional causes rather than primary testicular failure, addressing those root causes can restore the HPG axis without exogenous testosterone. The functional medicine evaluation always asks: is this primary hypogonadism (testicular failure) or secondary/functional hypogonadism (HPG axis suppression by reversible factors)?
Free Testosterone and SHBG: Why Total Testosterone Is Often Misleading
Standard laboratory panels measure total testosterone — the sum of protein-bound and free hormone. However, only free testosterone (approximately 2–3% of total) and loosely albumin-bound testosterone are biologically active. SHBG binds testosterone tightly, rendering it metabolically inert. As men age, SHBG rises significantly, meaning total testosterone can appear “normal” while free testosterone is profoundly deficient.
The Vermeulen equation (1999, Journal of Clinical Endocrinology & Metabolism) allows calculation of free testosterone from total testosterone, SHBG, and albumin — a critical step that most standard labs omit. Men with symptoms of hypogonadism (fatigue, low libido, cognitive fog, decreased muscle mass, depressed mood) but “normal” total testosterone frequently show low free testosterone when calculated via the Vermeulen method or directly measured by equilibrium dialysis.
Factors that raise SHBG — and therefore reduce free testosterone — include thyroid dysfunction, liver disease, caloric restriction, aging, and certain medications including statins. Factors that lower SHBG — increasing free testosterone availability — include insulin resistance, obesity, hypothyroidism, and anabolic steroid use. The functional medicine assessment therefore always includes SHBG alongside free testosterone, and investigates why SHBG may be elevated or dysregulated.
TRT Safety: What the TRAVERSE Trial Established
For years, the safety of testosterone replacement therapy with respect to cardiovascular events was uncertain following a 2010 study in the New England Journal of Medicine that was halted early due to increased adverse cardiovascular events in older hypogonadal men with mobility limitations. This created significant clinical uncertainty that persisted for over a decade.
The TRAVERSE trial (Lincoff and colleagues, 2023, New England Journal of Medicine) resolved much of this uncertainty. This large randomized controlled trial enrolled 5,246 men aged 45–80 with hypogonadism and pre-existing cardiovascular disease or elevated risk, randomizing to testosterone gel versus placebo over a median of 33 months. The primary finding: testosterone therapy was non-inferior to placebo for major adverse cardiovascular events (MACE) — including myocardial infarction, stroke, and cardiovascular death. The hazard ratio was 0.96 (95% CI 0.78–1.17), effectively clearing the cardiovascular safety concern for appropriately selected hypogonadal men.
The TRAVERSE trial did identify elevated rates of pulmonary embolism, atrial fibrillation, and acute kidney injury in the testosterone arm — findings that inform appropriate patient selection and monitoring. Men with pre-existing thromboembolic risk, polycythemia, or atrial fibrillation require careful risk-benefit evaluation before initiating TRT. The functional medicine approach prioritizes optimizing natural testosterone production before reaching the threshold for pharmaceutical replacement — but when TRT is indicated, the evidence now supports its cardiovascular safety profile.
Nutritional Optimization of Testosterone: Evidence-Based Interventions
Before pharmaceutical intervention, the functional medicine model systematically addresses nutritional deficiencies that impair testosterone synthesis, as the Leydig cell steroidogenesis pathway has multiple nutrient-dependent steps.
Zinc and Testosterone
Zinc functions as an essential cofactor in testosterone biosynthesis and inhibits aromatase — the enzyme that converts testosterone to estradiol. Prasad and colleagues (1996, Nutrition) demonstrated that dietary zinc restriction in young men reduced serum testosterone by approximately 75% over 20 weeks, and supplementation restored levels. In older men with marginal zinc deficiency, supplementation with 45mg/day for six months doubled testosterone concentrations. Zinc deficiency is common in men consuming high-grain diets (phytates bind zinc), in athletes with heavy sweat losses, and in men taking proton pump inhibitors or thiazide diuretics that increase urinary zinc excretion.
Vitamin D and Testosterone
Vitamin D receptors are expressed in Leydig cells, Sertoli cells, and throughout the male reproductive tract. Pilz and colleagues (2011, Hormone and Metabolic Research) conducted a one-year RCT in 165 overweight men, showing that 3,332 IU vitamin D3 daily produced a significant increase in total testosterone (+25%), free testosterone, and bioactive testosterone compared to placebo. Cross-sectional studies consistently show a positive correlation between 25-OH vitamin D levels and testosterone, with the association strongest below 30 ng/mL — precisely where the majority of men in northern latitudes spend much of the year.
Magnesium and Testosterone
Magnesium competes with SHBG for testosterone binding — higher intracellular and serum magnesium may increase free testosterone availability. Cinar and colleagues (2011, Biological Trace Element Research) found that magnesium supplementation (10 mg/kg/day for four weeks) significantly increased both free and total testosterone in sedentary men and athletes, with the effect amplified by exercise. Magnesium deficiency, present in an estimated 48% of Americans, also disrupts sleep quality and increases cortisol — both of which independently suppress testosterone.
Sleep, Cortisol, and the HPA-HPG Axis
The most dramatic and often overlooked testosterone intervention is sleep optimization. Leproult and Van Cauter (2011, JAMA) demonstrated that restricting sleep to 5 hours per night for one week reduced daytime testosterone levels by 10–15% in young healthy men — equivalent to approximately 10–15 years of aging-related decline. Cortisol and testosterone have reciprocal inhibitory relationships at both the hypothalamic and testicular levels. Chronic sleep deprivation, high-stress lifestyles, and HPA axis dysregulation are among the most potent suppressors of endogenous testosterone in functional clinical practice.
DHEA-S: The Longevity Biomarker Men Need to Know
Dehydroepiandrosterone sulfate (DHEA-S), produced by the adrenal cortex, is the most abundant circulating steroid hormone in humans and serves as a precursor to both testosterone and estradiol via peripheral conversion. DHEA-S peaks in the mid-20s and declines approximately 2% per year across the lifespan — one of the most reliable biological aging clocks available.
Low DHEA-S has been independently associated with all-cause mortality, cardiovascular disease, insulin resistance, immune senescence, and bone loss in multiple prospective cohort studies. The Rancho Bernardo Study followed 1,709 men for 12 years and found that those in the lowest quartile of DHEA-S had a 35% higher all-cause mortality risk compared to those in higher quartiles (Barrett-Connor and colleagues, 1986, NEJM). More recent data from the InCHIANTI study confirm the mortality association in both sexes.
In functional medicine practice, DHEA-S is measured alongside the full hormone panel and interpreted in the context of HPA axis function. Chronically elevated cortisol (from psychological stress, poor sleep, dysglycemia, or inflammation) directly suppresses DHEA production through competitive steroidogenesis — the adrenal glands prioritize cortisol synthesis over DHEA when under sustained stress load. Restoring DHEA-S often requires addressing upstream HPA axis drivers rather than supplementation alone.
When DHEA-S supplementation is clinically appropriate, typical physiologic dosing ranges from 25–50mg daily, with target serum DHEA-S in the upper quartile of the age-appropriate reference range. DHEA can aromatize to estradiol in peripheral tissues, making estrogen monitoring important particularly in men with obesity or insulin resistance.
Erectile Dysfunction as a Cardiovascular Biomarker
Erectile dysfunction (ED) is not merely a quality-of-life issue — it is a validated sentinel marker for systemic endothelial dysfunction and cardiovascular disease. The penile vasculature contains the smallest endothelium-dependent vessels in the body; endothelial dysfunction manifests there first, typically 3–5 years before coronary artery disease becomes clinically apparent.
Thompson and colleagues (2005, Journal of the American College of Cardiology) analyzed data from the Prostate Cancer Prevention Trial and found that men who developed ED during the study had a significantly elevated hazard ratio for subsequent cardiovascular events (HR 1.45, 95% CI 1.25–1.69) compared to those without ED. A 2018 meta-analysis in JAMA Internal Medicine confirmed this association across 92,757 men, finding that ED was associated with a 59% increased risk of cardiovascular events, 33% increased risk of stroke, and 37% increased risk of all-cause mortality.
The functional medicine implication is significant: a man presenting with ED at age 45–55 should be evaluated as a cardiovascular risk case, not merely referred for phosphodiesterase-5 inhibitor prescription. Advanced lipid panel (LP(a), LDL particle number, oxidized LDL), fasting insulin, homocysteine, high-sensitivity CRP, and coronary artery calcium (CAC) scoring are appropriate investigations. Endothelial function can be improved through the same interventions that improve cardiovascular risk: increasing dietary nitrate (arginine/citrulline precursors), reducing oxidative stress, optimizing vitamin D and testosterone, improving insulin sensitivity, and — critically — addressing sleep apnea, which is strongly associated with both ED and cardiovascular disease through nocturnal hypoxia-mediated endothelial injury.
Benign Prostatic Hyperplasia: Root Causes and Functional Interventions
Benign prostatic hyperplasia (BPH) affects roughly 50% of men by age 60 and 90% by age 85. The conventional model attributes BPH primarily to dihydrotestosterone (DHT) — the 5-alpha-reduced form of testosterone that is the primary androgen driving prostate cell proliferation. 5-alpha-reductase inhibitors (finasteride, dutasteride) reduce DHT by 60–90% and are effective for BPH, but carry risks including sexual dysfunction, depression, and persistent post-finasteride syndrome in a subset of men.
The functional medicine approach recognizes that estrogen — specifically estradiol and estrone — plays an underappreciated role in BPH through stimulation of stromal cell proliferation via estrogen receptor-beta in prostatic tissue. The age-related shift in the testosterone-to-estrogen ratio (as aromatase activity increases in adipose tissue with age and obesity) is a clinically modifiable driver of BPH that is distinct from the DHT pathway.
Saw Palmetto: Evaluating the Evidence
Saw palmetto (Serenoa repens) extract is the most extensively studied botanical intervention for BPH. Its proposed mechanism includes inhibition of 5-alpha-reductase (both type I and II), anti-inflammatory effects, and anti-estrogenic activity via inhibition of prostatic estrogen receptor binding. Earlier meta-analyses, including Wilt and colleagues’ 2002 Cochrane review, found significant improvements in urinary flow and symptom scores compared to placebo, with an effect size comparable to finasteride.
More recent large RCTs have produced mixed results: the STEP trial (Barry and colleagues, 2011, JAMA) found that escalating doses of saw palmetto extract (up to 960mg/day) produced no significant improvement over placebo in the American Urological Association Symptom Index. The clinical debate reflects important variation in extract quality and standardization — lipidosterolic extracts standardized to ≥85% fatty acids and sterols appear to have different bioactivity than poorly standardized commercial products. Observational data and smaller controlled trials continue to show benefit with pharmaceutical-grade extracts.
Zinc and Prostate Health
The prostate has the highest zinc concentration of any tissue in the body — healthy prostate epithelial cells accumulate zinc at concentrations 10× greater than serum levels. Zinc accumulation in prostate cells inhibits mitochondrial aconitase, diverting citrate toward secretion rather than oxidation — a critical function of normal prostate physiology. Prostate cancer cells uniformly lose this zinc-accumulating capacity, allowing citrate oxidation and energy generation for proliferation. Multiple case-control studies show inverse associations between dietary zinc intake and prostate cancer risk. Zinc also inhibits 5-alpha-reductase activity, supporting its relevance in both BPH and prostate cancer prevention.
Prostate Cancer Prevention: Sulforaphane, Lycopene, and the Evidence Base
Functional oncology approaches to prostate cancer prevention focus on modifiable dietary and biochemical factors that regulate prostate cell proliferation, apoptosis, and inflammation.
Sulforaphane and PSA Velocity
Sulforaphane — the isothiocyanate derived from glucoraphanin in cruciferous vegetables, particularly broccoli sprouts — has demonstrated significant activity against prostate cancer cells via NRF2 pathway activation, HDAC inhibition (epigenetic mechanism), and induction of cancer cell apoptosis. The most clinically relevant human evidence comes from Cipolla and colleagues (2015, Cancer Prevention Research), who conducted a randomized placebo-controlled trial in 78 men with rising PSA following radical prostatectomy. Those receiving broccoli seed and sprout extract (containing sulforaphane) showed an 86% lower PSA velocity compared to placebo — a dramatic effect size that positioned sulforaphane as a clinically meaningful intervention in biochemical recurrence settings.
The HDAC inhibition mechanism is particularly relevant: HDAC enzymes silence tumor suppressor genes in prostate cancer, and sulforaphane’s ability to inhibit HDACs restores expression of key cancer-suppressive genes including p21, Bax, and Nrf2 targets. Unlike pharmaceutical HDAC inhibitors, sulforaphane achieves this through a food-derived, broadly safe mechanism without significant toxicity.
Lycopene and Prostate Cancer Risk
Lycopene — the carotenoid responsible for the red color of tomatoes, watermelon, and pink grapefruit — concentrates preferentially in prostate tissue and has been associated with reduced prostate cancer risk in multiple epidemiological studies. Giovannucci and colleagues’ (1995) landmark analysis of the Health Professionals Follow-up Study found that men consuming tomato sauce ≥2 times per week had a 23% lower risk of prostate cancer compared to those consuming it less than once per month. Cooked tomato products provide more bioavailable lycopene than raw (isomerization during heating increases absorption).
Kucuk and colleagues (2002, Cancer Epidemiology, Biomarkers & Prevention) conducted an RCT in men awaiting radical prostatectomy, randomizing to lycopene supplementation (30mg/day) or placebo for three weeks preoperatively. The lycopene group showed significantly lower PSA levels, higher rates of tumor confinement to the prostate, and histological evidence of reduced prostate intraepithelial neoplasia — providing mechanistic support for lycopene’s prostate-protective properties. The proposed mechanisms include antioxidant quenching of reactive oxygen species, inhibition of cell cycle progression, and modulation of IGF-1 signaling in prostate cells.
The Complete Functional Men’s Health Assessment
A functional evaluation of men’s hormonal health extends well beyond a single testosterone measurement. The comprehensive assessment typically includes:
Hormonal panel: Total testosterone (morning, fasted), free testosterone (calculated or direct), SHBG, LH, FSH, estradiol (sensitive assay), DHEA-S, prolactin (if low testosterone with elevated LH ratio is absent), cortisol (4-point salivary or dried urine DUTCH Complete panel), thyroid panel (TSH, free T3, free T4, anti-TPO, anti-thyroglobulin).
Metabolic and nutritional: Fasting insulin, HbA1c, fasting glucose, advanced lipid panel, homocysteine, hs-CRP, ferritin, 25-OH vitamin D, zinc (RBC zinc or plasma), magnesium (RBC magnesium), complete metabolic panel (liver, kidney function), CBC with differential, PSA (age-appropriate).
Functional assessments: Body composition (DEXA scan or bioelectrical impedance), grip strength (validated sarcopenia screen), sleep study if symptoms suggest apnea (Berlin Questionnaire or STOP-BANG), bone density (DXA if hypogonadal >1 year), testicular ultrasound if structural pathology suspected.
This comprehensive picture allows differentiation between primary hypogonadism (elevated LH/FSH, low testosterone — testicular failure), secondary hypogonadism (low-normal LH/FSH, low testosterone — HPG suppression), and functional hypogonadism (HPG axis suppression by reversible metabolic factors). The treatment strategy differs substantially between these categories.
Lifestyle Interventions with the Strongest Evidence
Beyond specific nutrients, several lifestyle interventions have level-1 evidence for improving testosterone and men’s hormonal health:
Resistance training: High-intensity resistance exercise acutely elevates testosterone through neuromuscular mechanisms and, when practiced consistently, increases androgen receptor density and sensitivity. Craig and colleagues (1989, Medicine & Science in Sports & Exercise) established that compound multi-joint exercises (squat, deadlift, bench press) produce the largest acute testosterone responses. Long-term resistance training also reduces SHBG and improves insulin sensitivity — both mechanisms that increase free testosterone bioavailability.
Body fat reduction: Adipose tissue is a major site of aromatase activity — the enzyme that converts testosterone to estradiol. Obese men have significantly elevated aromatase activity, driving testosterone toward estrogen and creating a self-reinforcing cycle (lower testosterone → reduced muscle mass, increased fat → more aromatase → lower testosterone). Even modest body fat reduction (5–10% of body weight) measurably increases testosterone in hypogonadal overweight men through reduced aromatization alone.
Alcohol reduction: Chronic alcohol consumption suppresses the HPG axis through multiple mechanisms — Leydig cell toxicity, increased aromatase activity, elevated cortisol, zinc depletion, and disruption of LH pulsatility. Moderate alcohol consumption (≥14 drinks/week) consistently correlates with lower testosterone and elevated estradiol in men in cross-sectional studies. Even acute alcohol ingestion produces measurable testosterone suppression lasting 12–24 hours.
Frequently Asked Questions About Functional Men’s Health
What is the optimal free testosterone range for men?
Optimal free testosterone (calculated via Vermeulen equation or measured by equilibrium dialysis) for symptomatic assessment is generally considered 15–25 pg/mL or higher in men under 60, though symptom correlation matters more than absolute numbers. Men with symptoms of hypogonadism below 15 pg/mL typically respond well to interventions that raise free testosterone, whether through nutritional correction, sleep optimization, or when necessary, TRT.
Can testosterone naturally be optimized without TRT?
In functional (secondary) hypogonadism driven by sleep deprivation, obesity, nutritional deficiencies, or HPA axis dysregulation, yes — testosterone can be substantially restored through targeted interventions. Men with primary hypogonadism (elevated LH/FSH reflecting testicular failure) or age-related decline below 200 ng/dL with significant symptoms may ultimately require TRT, but functional optimization should always precede pharmaceutical intervention.
How does sleep apnea affect testosterone?
Sleep apnea causes nocturnal hypoxia during the hours when 70% of daily testosterone production occurs via pulsatile LH release. Untreated moderate-to-severe sleep apnea reduces testosterone by 15–25% compared to normal sleepers, independent of age and BMI. Effective CPAP therapy partially restores nocturnal testosterone production. Men presenting with low testosterone should be screened for sleep apnea, as it is one of the most common and reversible causes of functional hypogonadism.
Is PSA testing reliable for prostate cancer screening?
PSA has significant limitations as a standalone marker — BPH, prostatitis, and vigorous exercise all elevate PSA without malignancy, while some aggressive prostate cancers produce minimal PSA. More informative assessments include PSA velocity (rate of change over time), PSA density (adjusted for prostate volume), free-to-total PSA ratio (lower ratios indicate higher cancer probability), and newer biomarkers including the 4Kscore and phi (Prostate Health Index). Men on functional optimization protocols should establish baseline PSA and track velocity rather than relying on a single threshold value.
What role does insulin resistance play in testosterone decline?
Insulin resistance reduces testosterone through multiple converging pathways: hyperinsulinemia suppresses SHBG production by the liver (paradoxically increasing free testosterone initially, but this is accompanied by increased aromatization in visceral fat), chronic inflammation suppresses LH pulsatility and Leydig cell function, and the metabolic disruption of insulin resistance impairs the steroidogenesis pathway directly. Restoring insulin sensitivity through dietary modification (low-glycemic, reduced fructose), exercise, and targeted supplements (berberine, inositol, magnesium) often produces meaningful testosterone improvements in metabolically dysregulated men.
Working With a Functional Medicine Practitioner
Men’s hormonal optimization represents some of the highest-yield clinical work in functional medicine because the downstream effects — energy, cognition, body composition, cardiovascular health, mood, and longevity — are so pervasive. Yet the assessment requires precision: measuring the wrong markers, applying the wrong reference ranges, or missing a reversible cause of HPG suppression leads to unnecessary pharmaceutical dependency or missed opportunities for genuine restoration.
If you’re experiencing symptoms consistent with testosterone deficiency — fatigue, reduced motivation, cognitive fog, reduced muscle mass, decreased libido, mood changes, or sleep disruption — or if you’re concerned about prostate health, a comprehensive functional evaluation can identify exactly where your hormonal system is breaking down and which targeted interventions are most likely to restore function. To schedule a functional men’s health evaluation at The Private Practice, call (810) 206-1402.